08:00 , Dec 24, 2007 |  BC Week In Review  |  Company News

iTherX management update

ItherX Pharmaceuticals Inc. , San Diego, Calif.   Business: Cancer, Infectious   Hired: Jeffrey McKelvy as president, CEO and a director, formerly CEO of Avera Pharmaceuticals Inc. ; he succeeds Tsvi Goldenberg, who will remain...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Company News

Ceregene management update

Ceregene Inc. , San Diego, Calif.   Business: Gene/Cell therapy, Neurology   Hired: Joao Siffert as VP and CMO, formerly CMO at Avera Pharmaceuticals Inc.  ...
07:00 , Mar 26, 2007 |  BC Week In Review  |  Company News

Avera, Cornell University deal

Avera Pharmaceuticals Inc. , San Diego, Calif.   Cornell University , Ithaca, N.Y   Business: Neurology   The university granted Avera an exclusive, worldwide license to two preclinical anesthetics: AV002, a small molecule competitive antagonist...
07:00 , Oct 2, 2006 |  BC Week In Review  |  Clinical News

AV608: Completed Phase II enrollment

Avera completed enrollment of 182 patients in a double-blind, placebo-controlled, U.S. Phase II trial. Patients will receive a titrated dose of up to 160 mg daily of AV608 for 12 weeks. Avera Pharmaceuticals Inc. ,...
07:00 , Sep 18, 2006 |  BC Week In Review  |  Company News

Avera management update

Avera Pharmaceuticals Inc. , San Diego, Calif.   Business: Neurology   Hired: Dinu Sen as CEO, formerly chief commercial officer of Gilead Sciences Inc.'s Corus Pharmaceuticals Inc. unit; he replaces President and CEO Jeffrey McKelvy,...
23:49 , Sep 14, 2006 |  BC Extra  |  Company News

Avera names Sen CEO

Neurology company Avera (San Diego, Calif.) hired Dinu Sen as CEO. Sen replaces president and CEO Jeffrey McKelvy, who will remain president and become CTO. Previously, Sen was chief commercial officer of Corus , which...
07:00 , Jul 3, 2006 |  BC Week In Review  |  Clinical News

Gantacurium chloride: Phase II data

In a placebo- and succinylcholine-controlled, dose-response Phase II trial in 230 adults with American Society of Anesthesiologists (ASA) physical status classification 1 and 2 (healthy or mild systemic disease), gantacurium was well tolerated and met...
00:57 , Jun 28, 2006 |  BC Extra  |  Clinical News

Avera's gantacurium meets Phase II endpoint

Avera (San Diego, Calif.) said gantacurium ( AV430A ) achieved more than 90% acceptable intubations at 60 seconds after injection, the primary endpoint, in a Phase II trial as an adjunct to anesthesia for endotracheal...
07:00 , Jun 13, 2005 |  BC Week In Review  |  Company News

Avera management update

Avera Pharmaceuticals Inc. , San Diego, Calif.   Business: Neurology   Hired: Joao Siffert as VP of clinical R&D, formerly a medical director at Pfizer Inc.  ...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Company News

Kemia management update

Kemia Inc. , San Diego, Calif.   Business: Inflammation, Neurology, Cancer   Hired: Alison Pilgrim as CMO, formerly CMO at Avera Pharmaceuticals Inc.; and Bryan Jones as VP of business development, formerly associate director of...